Abstract
The dopamine transporter (DAT) is a target for the development of pharmacotherapies for a number of central disorders including Parkinsons disease, Alzheimers disease, schizophrenia, Tourettes syndrome, Lesch-Nyhan disease, attention deficit hyperactivity disorder (ADHD), obesity, depression, and stimulant abuse as well as normal aging. Considerable effort continues to be devoted to the development of new ligands for the DAT. In this review, we present some of the more interesting ligands developed during the last few years from the 3-phenytropane, 1,4-dialkylpiperazine, phenylpiperidine, and benztropine classes of DAT uptake inhibitors as well as a few less studied miscellaneous DAT uptake inhibitors. Studies related to the therapeutic potential of some of the more studied compounds are presented. A few of the compounds have been studied as pharmacotherapies for Parkinsons disease, ADHD, and obesity. However, most of the drug discovery studies have been directed toward pharmacotherapies for stimulant abuse (mainly cocaine). A number of the compounds showed decreased cocaine maintained responding in rhesus monkeys trained to self-administer cocaine. One compound, GBR 12,909, was evaluated in a Phase 1 clinical trial.
Keywords: Dopamine transporter, 3-phenyltropane, 1,4-dialkylpiperazine, phenylpiperidine, benztropine
Current Topics in Medicinal Chemistry
Title: Dopamine Transporter Ligands: Recent Developments and Therapeutic Potential
Volume: 6 Issue: 17
Author(s): Scott P. Runyon and F. Ivy Carroll
Affiliation:
Keywords: Dopamine transporter, 3-phenyltropane, 1,4-dialkylpiperazine, phenylpiperidine, benztropine
Abstract: The dopamine transporter (DAT) is a target for the development of pharmacotherapies for a number of central disorders including Parkinsons disease, Alzheimers disease, schizophrenia, Tourettes syndrome, Lesch-Nyhan disease, attention deficit hyperactivity disorder (ADHD), obesity, depression, and stimulant abuse as well as normal aging. Considerable effort continues to be devoted to the development of new ligands for the DAT. In this review, we present some of the more interesting ligands developed during the last few years from the 3-phenytropane, 1,4-dialkylpiperazine, phenylpiperidine, and benztropine classes of DAT uptake inhibitors as well as a few less studied miscellaneous DAT uptake inhibitors. Studies related to the therapeutic potential of some of the more studied compounds are presented. A few of the compounds have been studied as pharmacotherapies for Parkinsons disease, ADHD, and obesity. However, most of the drug discovery studies have been directed toward pharmacotherapies for stimulant abuse (mainly cocaine). A number of the compounds showed decreased cocaine maintained responding in rhesus monkeys trained to self-administer cocaine. One compound, GBR 12,909, was evaluated in a Phase 1 clinical trial.
Export Options
About this article
Cite this article as:
Runyon P. Scott and Carroll F. Ivy, Dopamine Transporter Ligands: Recent Developments and Therapeutic Potential, Current Topics in Medicinal Chemistry 2006; 6 (17) . https://dx.doi.org/10.2174/156802606778249775
DOI https://dx.doi.org/10.2174/156802606778249775 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Between Bench and Bed Side: PI3K Inhibitors
Current Molecular Pharmacology Resisting the Sun with Vitamin D
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Editorial: Management of Diabetes in Unique Populations
Current Diabetes Reviews Role of Diet and Nutrition on the Alteration of the Quality and Quantity of Stem Cells in Human Aging and the Diseases of Aging
Current Pharmaceutical Design Biophysical Screening for Identifying Pharmacological Chaperones and Inhibitors Against Conformational and Infectious Diseases
Current Drug Targets Mitochondrial Dysfunction in Gliomas: Pharmacotherapeutic Potential of Natural Compounds
Current Neuropharmacology Cytotoxic and Anticancer Activities of Isatin and Its Derivatives: A Comprehensive Review from 2000-2008
Anti-Cancer Agents in Medicinal Chemistry Biomarkers in Amyotrophic Lateral Sclerosis: Is There A Neurovascular Pathway?
Current Neurovascular Research Correct Protonation States and Relevant Waters = Better Computational Simulations?
Current Pharmaceutical Design Application of NMR Spectroscopy in Medicinal Chemistry and Drug Discovery
Current Topics in Medicinal Chemistry Prodrug Design of Phenolic Drugs
Current Pharmaceutical Design ENaC Modulators and Renal Disease
Current Molecular Pharmacology A Simple Extraction Procedure for HPLC Analysis of Fluoxetine in Rat Plasma Samples
Current Pharmaceutical Analysis Impact of Covid-19 on Mental Health: An Overview
Reviews on Recent Clinical Trials Application of Vibrational Spectroscopy to Study Solid-state Transformations of Pharmaceuticals
Current Pharmaceutical Design Ayahuasca, Psychedelic Studies and Health Sciences: The Politics of Knowledge and Inquiry into an Amazonian Plant Brew
Current Drug Abuse Reviews Advances in Drug Delivery Systems, from 0 to 3D superstructures
Current Drug Targets A Computational Framework to Identify Cross Association Between Complex Disorders by Protein-protein Interaction Network Analysis
Current Bioinformatics The Evil Axis of Obesity, Inflammation and Type-2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Synaptic Plasticity, Metaplasticity and Depression
Current Neuropharmacology